Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionIonQ Inc. Common Stock (IONQ)
Fair value
Not available
ACCE price target
$19.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST; previously $32.00 since 26 Sept 2026, 00:00 CEST.
Price used: $31.27 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
33
out of 100
Analysts
86% buy
14 covering
P/E
0.0x
forward 0.0x
1-year return
-47.3%
Dividend yield
0.00%
IonQ Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
IonQ builds trapped-ion quantum computers and sells access to them through cloud platforms and on-premises systems, with its current revenue coming from hardware sales and quantum computing services. The company's case rests on its trapped-ion approach, which it argues offers higher gate fidelity and easier scaling than competing superconducting designs, though that advantage is not yet visible in its financials. Revenue grew 286.8% over the period in the data, but operating margin is -408.2% and ROE is -60.5%, so growth is being bought with heavy losses. At a $14.1B market cap with no P/E because earnings are negative, the valuation depends almost entirely on whether revenue keeps compounding while losses narrow, and the 30.9% gross margin is the first number to watch for evidence of that. The stock scores 40/100 and sits in no index, so this is a speculative early-commercialization name, worth a deeper look only if the team is prepared to underwrite a long timeline on quantum adoption.